Taiwan · Delayed Price · Currency is TWD Lin BioScience Statistics
Total Valuation
Lin BioScience has a market cap or net worth of TWD 77.77 billion. The enterprise value is 76.24 billion.
| Market Cap | 77.77B |
| Enterprise Value | 76.24B |
Important Dates
The next estimated earnings date is Thursday, August 27, 2026.
| Earnings Date | Aug 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Lin BioScience has 82.83 million shares outstanding. The number of shares has increased by 3.48% in one year.
| Current Share Class | 82.83M |
| Shares Outstanding | 82.83M |
| Shares Change (YoY) | +3.48% |
| Shares Change (QoQ) | +1.56% |
| Owned by Insiders (%) | 18.57% |
| Owned by Institutions (%) | 6.91% |
| Float | 64.86M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 3.04 |
| P/TBV Ratio | 7.42 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 38.08, with a Debt / Equity ratio of 0.00.
| Current Ratio | 38.08 |
| Quick Ratio | 37.54 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | -1,966.51 |
Financial Efficiency
Return on equity (ROE) is -21.83% and return on invested capital (ROIC) is -16.00%.
| Return on Equity (ROE) | -21.83% |
| Return on Assets (ROA) | -15.73% |
| Return on Invested Capital (ROIC) | -16.00% |
| Return on Capital Employed (ROCE) | -15.49% |
| Weighted Average Cost of Capital (WACC) | 3.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -53.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +494.30% in the last 52 weeks. The beta is -0.16, so Lin BioScience's price volatility has been lower than the market average.
| Beta (5Y) | -0.16 |
| 52-Week Price Change | +494.30% |
| 50-Day Moving Average | 602.58 |
| 200-Day Moving Average | 435.23 |
| Relative Strength Index (RSI) | 69.12 |
| Average Volume (20 Days) | 1,679,941 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -3.97B |
| Pretax Income | -3.43B |
| Net Income | -1.61B |
| EBITDA | -3.96B |
| EBIT | -3.97B |
| Earnings Per Share (EPS) | -19.43 |
Balance Sheet
The company has 16.60 billion in cash and 92.72 million in debt, with a net cash position of 16.50 billion or 199.26 per share.
| Cash & Cash Equivalents | 16.60B |
| Total Debt | 92.72M |
| Net Cash | 16.50B |
| Net Cash Per Share | 199.26 |
| Equity (Book Value) | 25.56B |
| Book Value Per Share | 127.83 |
| Working Capital | 16.41B |
Cash Flow
In the last 12 months, operating cash flow was -2.26 billion and capital expenditures -19.39 million, giving a free cash flow of -2.28 billion.
| Operating Cash Flow | -2.26B |
| Capital Expenditures | -19.39M |
| Depreciation & Amortization | 14.63M |
| Net Borrowing | -21.55M |
| Free Cash Flow | -2.28B |
| FCF Per Share | -27.58 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Lin BioScience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.48% |
| Shareholder Yield | -3.48% |
| Earnings Yield | -2.07% |
| FCF Yield | -2.94% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |